Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02791230 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,733
- Enrollment target
NCT02791230 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,733 participants.
The verdict
NCT02791230, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,733 participants
- Enrollment target
Study Summary
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
Interventions
- DRUG Tafamidis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,733 participants |
| Start Date | 2016-06-13 |
| Est. Completion | 2023-11-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02791230
The ClinicalTrials.gov registry entry for NCT02791230 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,733 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tafamidis is the first listed.
NCT02791230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02791230 about?
NCT02791230 is a clinical study titled "Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy". Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
What is the current status of trial NCT02791230?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,733 participants. The study started on 2016-06-13. Estimated completion is 2023-11-02.
What interventions are being tested in trial NCT02791230?
The interventions under investigation include: Tafamidis (DRUG).
Who is sponsoring clinical trial NCT02791230?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.